UA71898C2 - Sustained release drug delivery system - Google Patents
Sustained release drug delivery system Download PDFInfo
- Publication number
- UA71898C2 UA71898C2 UA2000031729A UA2000031729A UA71898C2 UA 71898 C2 UA71898 C2 UA 71898C2 UA 2000031729 A UA2000031729 A UA 2000031729A UA 2000031729 A UA2000031729 A UA 2000031729A UA 71898 C2 UA71898 C2 UA 71898C2
- Authority
- UA
- Ukraine
- Prior art keywords
- agent
- covering layer
- coating layer
- layer
- impermeable
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title abstract description 8
- 239000012730 sustained-release form Substances 0.000 title abstract description 8
- 238000012377 drug delivery Methods 0.000 title abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 103
- 239000011247 coating layer Substances 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 24
- 230000009885 systemic effect Effects 0.000 claims abstract description 19
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 16
- 239000010410 layer Substances 0.000 claims description 151
- 239000003814 drug Substances 0.000 claims description 57
- 229940079593 drug Drugs 0.000 claims description 54
- 229920000642 polymer Polymers 0.000 claims description 39
- 230000003111 delayed effect Effects 0.000 claims description 19
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 18
- 238000000576 coating method Methods 0.000 claims description 18
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 18
- 239000013543 active substance Substances 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 16
- -1 steroid compounds Chemical class 0.000 claims description 16
- 238000009792 diffusion process Methods 0.000 claims description 12
- 229960002963 ganciclovir Drugs 0.000 claims description 12
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 12
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims description 11
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 11
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 11
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 10
- 238000002513 implantation Methods 0.000 claims description 10
- 210000004127 vitreous body Anatomy 0.000 claims description 10
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 229960000715 nimodipine Drugs 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 208000030533 eye disease Diseases 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 150000003431 steroids Chemical group 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 206010012692 Diabetic uveitis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- 230000001384 anti-glaucoma Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- ZINXKWMTURNPGZ-UHFFFAOYSA-N 3-fluoro-1h-pyrimidine-2,4-dione Chemical compound FN1C(=O)C=CNC1=O ZINXKWMTURNPGZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 230000031070 response to heat Effects 0.000 claims 1
- 238000013269 sustained drug release Methods 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 abstract description 2
- 210000001508 eye Anatomy 0.000 description 26
- 239000000126 substance Substances 0.000 description 17
- 241000124008 Mammalia Species 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000008901 benefit Effects 0.000 description 9
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940126585 therapeutic drug Drugs 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- 206010038910 Retinitis Diseases 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 239000004709 Chlorinated polyethylene Substances 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000181 Ethylene propylene rubber Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- GZZOCPZTALAJHU-GDTYSWHPSA-N OP(O)(O)=O.OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]1O Chemical compound OP(O)(O)=O.OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]1O GZZOCPZTALAJHU-GDTYSWHPSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- WVXOAWPSZWSWDX-UHFFFAOYSA-K P(=O)(=O)C(=O)[O-].[Na+].[Na+].[Na+].P(=O)(=O)C(=O)[O-].P(=O)(=O)C(=O)[O-] Chemical compound P(=O)(=O)C(=O)[O-].[Na+].[Na+].[Na+].P(=O)(=O)C(=O)[O-].P(=O)(=O)C(=O)[O-] WVXOAWPSZWSWDX-UHFFFAOYSA-K 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- CNIIGCLFLJGOGP-UHFFFAOYSA-N SJ000285664 Natural products C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 229920001986 Vinylidene chloride-vinyl chloride copolymer Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- VEHZBMGMMPZMRJ-UHFFFAOYSA-N acetic acid;2-(diethylamino)acetic acid Chemical compound CC(O)=O.CCN(CC)CC(O)=O VEHZBMGMMPZMRJ-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- IKZZIQXKLWDPCD-UHFFFAOYSA-N but-1-en-2-ol Chemical compound CCC(O)=C IKZZIQXKLWDPCD-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229960003715 demecarium bromide Drugs 0.000 description 1
- YHKBUDZECQDYBR-UHFFFAOYSA-L demecarium bromide Chemical compound [Br-].[Br-].C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 YHKBUDZECQDYBR-UHFFFAOYSA-L 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 229920006244 ethylene-ethyl acrylate Polymers 0.000 description 1
- 229950002420 eucatropine Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229950005360 hydroxyamfetamine Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000012229 microporous material Substances 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920005670 poly(ethylene-vinyl chloride) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000002544 virustatic Substances 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/919,221 US5902598A (en) | 1997-08-28 | 1997-08-28 | Sustained release drug delivery devices |
| PCT/US1998/017342 WO1999011244A1 (fr) | 1997-08-28 | 1998-08-28 | Dispositifs d'administration de medicament a degagement prolonge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA71898C2 true UA71898C2 (en) | 2005-01-17 |
Family
ID=25441727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000031729A UA71898C2 (en) | 1997-08-28 | 1998-08-28 | Sustained release drug delivery system |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5902598A (fr) |
| EP (1) | EP1009388B1 (fr) |
| JP (2) | JP4530531B2 (fr) |
| KR (1) | KR20010023358A (fr) |
| CN (2) | CN101327197A (fr) |
| AR (1) | AR017026A1 (fr) |
| AT (1) | ATE548029T1 (fr) |
| AU (1) | AU741846B2 (fr) |
| BR (1) | BR9811381A (fr) |
| CA (1) | CA2301685C (fr) |
| CZ (1) | CZ302339B6 (fr) |
| EA (1) | EA002162B1 (fr) |
| HK (1) | HK1035135A1 (fr) |
| HU (1) | HUP0002797A3 (fr) |
| IL (1) | IL134568A (fr) |
| ME (2) | MEP20008A (fr) |
| NO (1) | NO327752B1 (fr) |
| NZ (2) | NZ502836A (fr) |
| PL (1) | PL344039A1 (fr) |
| RS (1) | RS52096B (fr) |
| SG (1) | SG121718A1 (fr) |
| TR (1) | TR200001029T2 (fr) |
| TW (1) | TWI222884B (fr) |
| UA (1) | UA71898C2 (fr) |
| WO (1) | WO1999011244A1 (fr) |
Families Citing this family (266)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6117643A (en) * | 1997-11-25 | 2000-09-12 | Ut Battelle, Llc | Bioluminescent bioreporter integrated circuit |
| CA2358296A1 (fr) * | 1999-01-05 | 2000-07-13 | Anthony P. Adamis | Administration ciblee de medicament a liberation regulee vers la retine et la choroide a travers la sclerotique |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US20040121014A1 (en) * | 1999-03-22 | 2004-06-24 | Control Delivery Systems, Inc. | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| ES2231257T3 (es) | 1999-10-21 | 2005-05-16 | Alcon Inc. | Dispositivo para la administracion de farmacos. |
| US7943162B2 (en) * | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| EP1522289A3 (fr) | 1999-10-21 | 2008-01-23 | Alcon, Inc | Administration sous-tendineuse de médicaments. |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| US20040175410A1 (en) * | 2000-04-26 | 2004-09-09 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| US20040115268A1 (en) * | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| US20040208910A1 (en) * | 2000-04-26 | 2004-10-21 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of adrenergic agents |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| US20040170955A1 (en) * | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| US20050074747A1 (en) * | 2000-09-08 | 2005-04-07 | Wadih Arap | Biopanning and rapid analysis of selective interactive ligands (brasil) |
| US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
| US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| US20020169162A1 (en) * | 2000-11-03 | 2002-11-14 | Smith Thomas J. | Device and method for treating conditions of a joint |
| AU3649502A (en) | 2000-11-29 | 2002-06-11 | Oculex Pharm Inc | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| WO2002056863A2 (fr) | 2000-12-29 | 2002-07-25 | Bausch & Lomb Incorporated | Dispositif d'apport de medicaments en continu |
| WO2002053130A2 (fr) * | 2001-01-03 | 2002-07-11 | Bausch & Lomb Incorporated | Dispositifs de liberation prolongee de medicaments comprenant des noyaux de medicaments enrobes |
| US6964781B2 (en) * | 2001-01-03 | 2005-11-15 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with prefabricated permeable plugs |
| EP1847255A3 (fr) * | 2001-01-03 | 2009-03-04 | Bausch & Lomb Incorporated | Dispositifs de livraison de médicaments à libération prolongée avec noyaux de médicaments recouverts |
| CA2432203C (fr) | 2001-01-03 | 2008-03-25 | Michael J. Brubaker | Dispositifs d'administration de medicament a liberation prolongee pour la diffusion d'agents multiples |
| JP2004520900A (ja) * | 2001-01-26 | 2004-07-15 | ボシュ・アンド・ロム・インコーポレイテッド | 徐放薬剤送達装置の改良製造方法 |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
| US8728445B2 (en) | 2001-05-01 | 2014-05-20 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel Compositions |
| US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
| US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
| EP1390084B1 (fr) * | 2001-05-01 | 2011-03-23 | A.V. Topchiev Institute of Petrochemical Synthesis | Composition bioadhesive biphase absorbant l'eau |
| US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| US7563255B2 (en) | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
| DE60239868D1 (de) | 2001-06-12 | 2011-06-09 | Univ Johns Hopkins Med | Reservoirvorrichtung für die intraokulare arzneimittelabgabe |
| EP1418932A4 (fr) * | 2001-07-18 | 2006-03-15 | Univ Texas | Etat anti-angiogene chez les souris et les etres humains souffrant d'une degenerescence cellulaire du photorecepteur retinien |
| JP4249611B2 (ja) * | 2001-07-23 | 2009-04-02 | アルコン，インコーポレイティド | 眼薬剤送致装置 |
| DE60217679T2 (de) | 2001-07-23 | 2007-10-25 | Alcon Inc. | Vorrichtung zur freisetzung eines ophthalmischen arzneimittels |
| US7749528B2 (en) * | 2001-08-29 | 2010-07-06 | Ricardo Azevedo Pontes De Carvalho | Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
| US7195774B2 (en) | 2001-08-29 | 2007-03-27 | Carvalho Ricardo Azevedo Ponte | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| US20040048243A1 (en) * | 2001-09-07 | 2004-03-11 | Wadih Arap | Methods and compositions for in vitro targeting |
| US8507445B2 (en) * | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US7671010B2 (en) * | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| US20030158598A1 (en) * | 2001-09-17 | 2003-08-21 | Control Delivery Systems, Inc. | System for sustained-release delivery of anti-inflammatory agents from a coated medical device |
| US8304047B2 (en) * | 2002-01-31 | 2012-11-06 | Vestergaard Frandsen Sa | Laminated insecticide dispenser |
| WO2003071986A2 (fr) * | 2002-02-22 | 2003-09-04 | Control Delivery Systems, Inc. | Methode de traitement de troubles otiques |
| CA2478772C (fr) * | 2002-03-11 | 2011-01-18 | Alcon, Inc. | Systeme de distribution de medicament implantable |
| MXPA04010282A (es) * | 2002-04-18 | 2005-08-18 | Acuity Pharmaceuticals Inc | Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo. |
| AU2003234294A1 (en) * | 2002-05-02 | 2003-11-17 | Control Delivery Systems, Inc. | Device and method for treating conditions of a joint |
| WO2003092665A2 (fr) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Systemes oculaires de distribution de medicament et utilisation associee |
| WO2003094888A1 (fr) * | 2002-05-07 | 2003-11-20 | Control Delivery Systems, Inc. | Procedes de fabrication d'un distributeur de medicaments |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| JP4615309B2 (ja) | 2002-05-17 | 2011-01-19 | オセラ・ホールディング・インコーポレイテッド | 白内障および他の眼球疾患の進行の改善 |
| ES2295647T3 (es) | 2002-07-15 | 2008-04-16 | Alcon, Inc. | Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular. |
| US20070184089A1 (en) * | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
| US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| WO2004036182A2 (fr) * | 2002-10-17 | 2004-04-29 | Control Delivery Systems, Inc. | Procede de suivi de traitement de maladie |
| AU2003287666A1 (en) * | 2002-11-13 | 2004-06-03 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| CA2453013C (fr) * | 2002-12-13 | 2011-02-15 | Gary W. Cleary | Dispositifs d'administration d'ingredients par voie percutanee, transdermique ou transmuqueuse ou par les muqueuses |
| WO2004058272A1 (fr) * | 2002-12-20 | 2004-07-15 | Control Delivery Systems, Inc. | Compositions de steroides pour utilisation intraoculaire |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| EP2251434B1 (fr) | 2003-01-16 | 2014-07-30 | The Trustees of The University of Pennsylvania | Compositions et procedes destines a l'inhibition du gene icam-1 par arn a faible inhibition |
| CN1741793A (zh) * | 2003-01-24 | 2006-03-01 | 控释给药系统公司 | 高可溶性药物的控制释放 |
| KR20050108345A (ko) * | 2003-01-24 | 2005-11-16 | 컨트롤 딜리버리 시스템즈 인코포레이티드 | 탄산 탈수효소 저해제의 안구 전달을 위한 서방 장치와방법 |
| SI1592408T1 (sl) * | 2003-01-24 | 2010-01-29 | Psivida Inc | Naprava s podaljšanim sproščanjem in postopek za okularno dajanje adrenergičnih sredstev |
| WO2004066939A2 (fr) * | 2003-01-27 | 2004-08-12 | Sarnoff Corporation | Systeme d'administration de medicament a liberation controlee |
| WO2004073551A2 (fr) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Dispositif d'administration transsclerale de medicament et procedes associes |
| US9445901B2 (en) * | 2003-03-12 | 2016-09-20 | Deger C. Tunc | Prosthesis with sustained release analgesic |
| US7037521B2 (en) * | 2003-03-28 | 2006-05-02 | Bausch & Lomb Incorporated | Using a laser for cutting a hole in a capsule for controlled drug delivery |
| US20050261668A1 (en) * | 2003-03-28 | 2005-11-24 | Bausch & Lomb Incorporated | Drug delivery device |
| US7589107B2 (en) | 2003-05-19 | 2009-09-15 | Othera Holding, Inc. | Amelioration of vitrectomy-induced cataracts |
| US7825134B2 (en) * | 2003-05-19 | 2010-11-02 | Othera Holding, Inc. | Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
| US7850660B2 (en) | 2003-12-19 | 2010-12-14 | Ethicon Endo-Surgery, Inc. | Implantable medical device with simultaneous attachment mechanism and method |
| US8715243B2 (en) * | 2003-06-16 | 2014-05-06 | Ethicon Endo-Surgery, Inc. | Injection port applier with downward force actuation |
| US7862546B2 (en) * | 2003-06-16 | 2011-01-04 | Ethicon Endo-Surgery, Inc. | Subcutaneous self attaching injection port with integral moveable retention members |
| US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
| WO2005001079A2 (fr) | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Reparation et regeneration des tissus mous a l'aide de cellules provenant de tissus post-partum |
| US20100158880A1 (en) * | 2008-12-19 | 2010-06-24 | Ethicon, Incorporated | Regeneration and repair of neural tissue following injury |
| US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
| US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
| US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
| US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
| US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
| US20040265356A1 (en) * | 2003-06-30 | 2004-12-30 | Bausch & Lomb Incorporated | Drug delivery device |
| US20050054586A1 (en) * | 2003-06-30 | 2005-03-10 | Bartels Stephen P. | Treatment of ophthalmic disorders |
| CA2530996C (fr) * | 2003-07-03 | 2013-05-07 | Corium International, Inc. | Pansement, dispositif d'administration d'ingredient et dispositif de fixation intraveineux et procede associe |
| KR20060082792A (ko) * | 2003-07-10 | 2006-07-19 | 알콘, 인코퍼레이티드 | 안과용 약물 전달 장치 |
| US7585517B2 (en) * | 2003-09-18 | 2009-09-08 | Macusight, Inc. | Transscleral delivery |
| AU2004292957C1 (en) * | 2003-11-13 | 2011-04-28 | Eyepoint Pharmaceuticals Us, Inc. | Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin |
| CN100558360C (zh) | 2003-11-20 | 2009-11-11 | 奥特拉控股公司 | 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途 |
| US20050148948A1 (en) * | 2003-12-19 | 2005-07-07 | Caputa Steven G. | Sutureless ophthalmic drug delivery system and method |
| US8162897B2 (en) * | 2003-12-19 | 2012-04-24 | Ethicon Endo-Surgery, Inc. | Audible and tactile feedback |
| DE10360185A1 (de) * | 2003-12-20 | 2005-08-04 | Max Wyssmann | Vorrichtung zur gezielten, steuerbaren Abgabe oder zum Ansaugen einer Flüssigkeit oder einer viskosen Masse |
| US20050137538A1 (en) * | 2003-12-22 | 2005-06-23 | Bausch & Lomb Incorporated | Drug delivery device |
| US20050158365A1 (en) | 2003-12-22 | 2005-07-21 | David Watson | Drug delivery device with mechanical locking mechanism |
| US7211272B2 (en) * | 2003-12-22 | 2007-05-01 | Bausch & Lomb Incorporated | Drug delivery device |
| US20050136095A1 (en) * | 2003-12-22 | 2005-06-23 | Brian Levy | Drug delivery device with suture ring |
| WO2005070333A1 (fr) | 2004-01-13 | 2005-08-04 | Orthobiologica, Inc. | Administration d'un medicament a une articulation |
| EP1718274A2 (fr) * | 2004-01-26 | 2006-11-08 | Control Delivery Systems, Inc. | Liberation controlee et prolongee d'agents therapeutiques a base d'acide nucleique |
| US8658201B2 (en) | 2004-01-30 | 2014-02-25 | Corium International, Inc. | Rapidly dissolving film for delivery of an active agent |
| US20060018949A1 (en) * | 2004-04-07 | 2006-01-26 | Bausch & Lomb Incorporated | Injectable biodegradable drug delivery system |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20070254950A1 (en) * | 2004-05-25 | 2007-11-01 | Othera Pharmaceuticals, Inc. | Oculoselective Drugs and Prodrugs |
| CA2572223C (fr) | 2004-06-25 | 2014-08-12 | The Johns Hopkins University | Inhibiteurs d'angiogenese |
| US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
| US7922702B2 (en) | 2004-07-02 | 2011-04-12 | Qlt Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
| CN101039706A (zh) * | 2004-08-05 | 2007-09-19 | 考里安国际公司 | 粘合剂组合物 |
| US20060068012A1 (en) * | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control |
| US20060067978A1 (en) * | 2004-09-29 | 2006-03-30 | Bausch & Lomb Incorporated | Process for preparing poly(vinyl alcohol) drug delivery devices |
| US20060067979A1 (en) * | 2004-09-30 | 2006-03-30 | Bausch & Lomb Incorporated | Ophthalmic drug release device for multiple drug release |
| WO2006039459A1 (fr) * | 2004-09-30 | 2006-04-13 | Bausch & Lomb Incorporated | Capsule pour envelopper des comprimes pour une insertion chirurgicale dans le corps humain |
| US20060078592A1 (en) * | 2004-10-12 | 2006-04-13 | Bausch & Lomb Incorporated | Drug delivery systems |
| US20070276481A1 (en) * | 2004-12-08 | 2007-11-29 | Renner Steven B | Drug delivery device |
| US20060134162A1 (en) * | 2004-12-16 | 2006-06-22 | Larson Christopher W | Methods for fabricating a drug delivery device |
| US20060166361A1 (en) * | 2004-12-21 | 2006-07-27 | Agnieszka Seyda | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
| WO2006101548A2 (fr) * | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Cellules post-partum derivees du tissu du cordon ombilical et leurs procedes de fabrication, de mise en culture et d'utilisation |
| US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
| US20060134174A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
| WO2006068898A1 (fr) * | 2004-12-22 | 2006-06-29 | Bausch & Lomb Incorporated | Dispositif de distribution de medicament reutilisable |
| US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
| JP5340599B2 (ja) | 2004-12-23 | 2013-11-13 | エシコン・インコーポレイテッド | 臍帯組織由来産褥細胞ならびにその製造方法および使用方法 |
| JP5425400B2 (ja) | 2004-12-23 | 2014-02-26 | エシコン・インコーポレイテッド | 産褥由来細胞を用いた脳卒中および他の急性神経変性障害の治療 |
| US20060257450A1 (en) * | 2005-03-21 | 2006-11-16 | Sreenivasu Mudumba | Drug delivery systems for treatment of diseases or conditions |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| BRPI0608152A2 (pt) | 2005-02-09 | 2009-11-10 | Macusight Inc | formulações para tratamento ocular |
| CA2601864A1 (fr) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Implants a liberation prolongee et methodes d'administration sous-retinienne d'agents bioactifs pour traiter ou prevenir les maladies de la retine |
| US20080312283A1 (en) * | 2005-05-26 | 2008-12-18 | Othera Pharmaceuticals, Inc. | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts |
| US7651483B2 (en) * | 2005-06-24 | 2010-01-26 | Ethicon Endo-Surgery, Inc. | Injection port |
| US7918844B2 (en) | 2005-06-24 | 2011-04-05 | Ethicon Endo-Surgery, Inc. | Applier for implantable medical device |
| US20060292202A1 (en) * | 2005-06-27 | 2006-12-28 | Bausch & Lomb Incorporated | Drug delivery device |
| KR20080033463A (ko) | 2005-07-27 | 2008-04-16 | 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. | 단백질 미스폴딩을 보정하는 작은 화합물 및 그의 용도 |
| US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
| US20080293691A1 (en) | 2005-11-29 | 2008-11-27 | Smithkline Beecham Corporation | Treatment Method |
| AU2006325710B2 (en) * | 2005-12-16 | 2012-05-17 | Ethicon, Inc. | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
| ES2628129T3 (es) * | 2005-12-28 | 2017-08-01 | DePuy Synthes Products, Inc. | Tratamiento de la enfermedad vascular periférica utilizando células derivadas del posparto |
| US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
| US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| WO2007092620A2 (fr) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Formulations stables et leurs procedes de preparation et d'utilisation |
| US20070203190A1 (en) * | 2006-02-22 | 2007-08-30 | Ghanshyam Patil | Hydroxylamines and derivatives for the inhibition of complement activation |
| CA2645488C (fr) | 2006-03-23 | 2014-09-02 | Macusight, Inc. | Formulations comprenant de la rapamycine et methodes d'utilisation de celle-ci destinees aux maladies ou aux pathologies liees a la permeabilite vasculaire |
| JP2009532132A (ja) | 2006-03-31 | 2009-09-10 | キューエルティー プラグ デリバリー，インク． | 薬物治療用鼻涙排液系インプラント |
| US20090130212A1 (en) * | 2006-05-15 | 2009-05-21 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
| WO2007146953A2 (fr) * | 2006-06-12 | 2007-12-21 | Exegenics, Inc., D/B/A Opko Health, Inc. | COMPOSITIONS ET PROCÉDÉS DESTINÉS À UNE INHIBITION DE L'ANGIOGENÈSE PAR LES ARNsi |
| US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8802128B2 (en) * | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| CA2660151C (fr) * | 2006-08-07 | 2012-04-17 | Bausch & Lomb Incorporated | Compositions et procedes pour traiter, controler, reduire ou ameliorer les infections et les sequelles de celles-ci |
| MX2009002228A (es) * | 2006-08-31 | 2009-04-17 | Bausch & Lomb | Composiciones y metodos para tratar o prevenir glaucoma o el avance del mismo. |
| US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
| PT2061444E (pt) * | 2006-09-11 | 2011-07-08 | Bausch & Lomb | Composições e métodos de tratamento, controlo, redução, melhoramento ou prevenção de alergias |
| US20110105559A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy |
| US20110104159A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
| US20080145405A1 (en) * | 2006-12-15 | 2008-06-19 | Kunzler Jay F | Drug delivery devices |
| GB0713463D0 (en) | 2007-07-11 | 2007-08-22 | Btg Int Ltd | Modulators of hypoxia inducible factor-1 and related uses |
| CN105998028A (zh) | 2007-02-22 | 2016-10-12 | 科尔比制药公司 | 羟胺化合物及其用法 |
| US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
| US20090042936A1 (en) * | 2007-08-10 | 2009-02-12 | Ward Keith W | Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation |
| US20090087443A1 (en) * | 2007-09-27 | 2009-04-02 | Bartels Stephen P | Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery |
| AU2008308531B2 (en) * | 2007-10-05 | 2014-04-24 | Ethicon, Incorporated | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
| US20100152646A1 (en) * | 2008-02-29 | 2010-06-17 | Reshma Girijavallabhan | Intravitreal injection device and method |
| US9023063B2 (en) | 2008-04-17 | 2015-05-05 | Apollo Endosurgery, Inc. | Implantable access port device having a safety cap |
| EP2471572A3 (fr) * | 2008-04-17 | 2012-10-17 | Allergan, Inc. | Dispositif de port d'accès implantable |
| US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
| US20100121441A1 (en) * | 2008-11-10 | 2010-05-13 | Nabil Jabbour | Surgical implant and method |
| CA2745832A1 (fr) | 2008-12-04 | 2010-06-10 | Opko Ophthalmics, Llc | Compositions et procedes pour l'inhibition selective d'isoformes pro-angiogeniques de vegf |
| US20100143437A1 (en) * | 2008-12-09 | 2010-06-10 | Morris Edward J | Implantable analgesic |
| BRPI0923177A2 (pt) * | 2008-12-19 | 2020-08-25 | Advanced Technologies And Regenerative Medicine, Llc | usos de composições para tratar dor neuropática e espacidade, as referidas composições, e kit |
| CN107028983A (zh) | 2008-12-19 | 2017-08-11 | 德普伊新特斯产品有限责任公司 | 肺部疾病和病症的治疗 |
| US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
| AU2010204986B2 (en) | 2009-01-14 | 2016-06-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| CA3045436A1 (fr) | 2009-01-29 | 2010-08-05 | Forsight Vision4, Inc. | Administration d'un medicament dans le segment posterieur |
| US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| US8722034B2 (en) * | 2009-03-26 | 2014-05-13 | Depuy Synthes Products Llc | hUTC as therapy for Alzheimer's disease |
| US20110077270A1 (en) * | 2009-04-21 | 2011-03-31 | Pfeffer Bruce A | Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure |
| US8632511B2 (en) * | 2009-05-06 | 2014-01-21 | Alcon Research, Ltd. | Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| JP5937004B2 (ja) * | 2009-05-18 | 2016-06-22 | ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ | 薬剤溶出眼内インプラント |
| EP4108216A1 (fr) | 2009-06-03 | 2022-12-28 | Forsight Vision5, Inc. | Administration de médicaments de segment antérieur |
| IN2012DN00352A (fr) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
| US8708979B2 (en) | 2009-08-26 | 2014-04-29 | Apollo Endosurgery, Inc. | Implantable coupling device |
| US8715158B2 (en) | 2009-08-26 | 2014-05-06 | Apollo Endosurgery, Inc. | Implantable bottom exit port |
| US8506532B2 (en) | 2009-08-26 | 2013-08-13 | Allergan, Inc. | System including access port and applicator tool |
| WO2011039648A1 (fr) | 2009-09-30 | 2011-04-07 | Glaxo Wellcome Manufacturing Pte Ltd. | Procédé d'administration et de traitement |
| RU2012127772A (ru) * | 2009-12-04 | 2014-01-10 | ОПКО ОФТЭЛМИКС, ЭлЭлСи | Композиции и способы для ингибирования vegf |
| US8177747B2 (en) * | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
| EP2515864A4 (fr) * | 2009-12-23 | 2013-09-11 | Psivida Inc | Dispositifs d'administration à libération prolongée |
| WO2013022801A1 (fr) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Administration de petites molécules à l'aide d'un dispositif thérapeutique implantable |
| US20110189174A1 (en) | 2010-02-01 | 2011-08-04 | Afshin Shafiee | Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization |
| US8882728B2 (en) | 2010-02-10 | 2014-11-11 | Apollo Endosurgery, Inc. | Implantable injection port |
| US20110270021A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Electronically enhanced access port for a fluid filled implant |
| US8992415B2 (en) | 2010-04-30 | 2015-03-31 | Apollo Endosurgery, Inc. | Implantable device to protect tubing from puncture |
| US20110270025A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Remotely powered remotely adjustable gastric band system |
| JP2013526572A (ja) * | 2010-05-17 | 2013-06-24 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | 眼治療薬の送達のための薬物送達装置 |
| US8939948B2 (en) | 2010-06-01 | 2015-01-27 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
| EP2585057B1 (fr) | 2010-06-25 | 2017-08-23 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Méthode de traitement en utilisant acide sterculique |
| JP5907966B2 (ja) | 2010-08-05 | 2016-04-26 | フォーサイト・ビジョン フォー・インコーポレーテッド | 埋め込み型治療デバイス |
| WO2012019139A1 (fr) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Procédés et appareils d'administration combinée de médicament |
| US9033911B2 (en) | 2010-08-05 | 2015-05-19 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
| US20120041258A1 (en) | 2010-08-16 | 2012-02-16 | Allergan, Inc. | Implantable access port system |
| US20120065460A1 (en) | 2010-09-14 | 2012-03-15 | Greg Nitka | Implantable access port system |
| EP2640360A2 (fr) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Formulations d'agents thérapeutiques pour des dispositifs implantés |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| WO2012080833A2 (fr) | 2010-12-13 | 2012-06-21 | Purdue Pharma L.P. | Formes pharmaceutiques permettant une libération contrôlée |
| US8821373B2 (en) | 2011-05-10 | 2014-09-02 | Apollo Endosurgery, Inc. | Directionless (orientation independent) needle injection port |
| US20120316199A1 (en) | 2011-06-07 | 2012-12-13 | Ward Keith W | Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| JP6068457B2 (ja) | 2011-06-14 | 2017-01-25 | ビカム ファーマスーティカルス，インコーポレイテッド | 化合物及び組成物 |
| WO2013003620A2 (fr) | 2011-06-28 | 2013-01-03 | Forsight Vision4, Inc. | Procédés et appareil de diagnostic |
| US8801597B2 (en) | 2011-08-25 | 2014-08-12 | Apollo Endosurgery, Inc. | Implantable access port with mesh attachment rivets |
| CN103889401B (zh) | 2011-08-29 | 2017-10-13 | Qlt公司 | 持续释放递送活性剂以治疗青光眼和高眼压 |
| US9974685B2 (en) | 2011-08-29 | 2018-05-22 | Mati Therapeutics | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
| EP3903733A1 (fr) | 2011-09-16 | 2021-11-03 | ForSight Vision4, Inc. | Appareil d'échange de fluide |
| EP2768307B1 (fr) | 2011-10-19 | 2020-03-18 | Bikam Pharmaceuticals, Inc. | Ligands de liaison à une opsine, compositions et procédés d'utilisation |
| US9199069B2 (en) | 2011-10-20 | 2015-12-01 | Apollo Endosurgery, Inc. | Implantable injection port |
| US8858421B2 (en) | 2011-11-15 | 2014-10-14 | Apollo Endosurgery, Inc. | Interior needle stick guard stems for tubes |
| US9089395B2 (en) | 2011-11-16 | 2015-07-28 | Appolo Endosurgery, Inc. | Pre-loaded septum for use with an access port |
| US9353063B2 (en) | 2011-11-30 | 2016-05-31 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
| US10040749B2 (en) | 2011-12-01 | 2018-08-07 | Bikam Pharmaceuticals Inc. | Opsin-binding ligands, compositions and methods of use |
| AU2012358810B2 (en) | 2011-12-23 | 2018-03-15 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue-derived cells |
| EP2806828B1 (fr) | 2012-01-24 | 2021-07-21 | The Regents of The University of Colorado, A Body Corporate | Conceptions de lentilles intraoculaires modulaires et procédés s'y rapportant |
| US10080648B2 (en) | 2012-01-24 | 2018-09-25 | Clarvista Medical, Inc. | Modular intraocular lens designs, tools and methods |
| US10028824B2 (en) | 2012-01-24 | 2018-07-24 | Clarvista Medical, Inc. | Modular intraocular lens designs, tools and methods |
| US9364316B1 (en) * | 2012-01-24 | 2016-06-14 | Clarvista Medical, Inc. | Modular intraocular lens designs, tools and methods |
| WO2013116061A1 (fr) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Procédés et instrument pour l'insertion et le retrait de dispositifs thérapeutiques |
| KR101969594B1 (ko) * | 2012-05-11 | 2019-04-16 | 서강대학교산학협력단 | 안내 약물 전달 임플란트 |
| PT2911623T (pt) | 2012-10-26 | 2019-11-21 | Forsight Vision5 Inc | Sistema oftálmico para libertação prolongada de fármaco no olho |
| CA2940513C (fr) | 2013-03-11 | 2023-08-15 | University Of Florida Research Foundation, Inc. | Delivrance d'une proteine a domaine de recrutement des caspases (card) en tant que therapie pour inflammation oculaire |
| EP2968113B8 (fr) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systèmes pour l'administration intra-oculaire entretenue de composés à faible solubilité provenant d'un implant de système de pose d'orifice |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| CA2907681C (fr) | 2013-03-28 | 2022-11-22 | Forsight Vision4, Inc. | Implant ophtalmique pour administrer des substances therapeutiques |
| US10098836B2 (en) | 2013-05-02 | 2018-10-16 | Retina Foundation Of The Southwest | Method for forming a molded two-layer ocular implant |
| ES2740352T3 (es) * | 2013-11-14 | 2020-02-05 | Eyed Pharma | Dispositivo ocular |
| EP3068371A1 (fr) * | 2013-11-15 | 2016-09-21 | Glaukos Corporation | Implants oculaires conçus pour stocker et libérer des formulations de médicaments stables |
| EP4215159A1 (fr) | 2014-02-18 | 2023-07-26 | Alcon Inc. | Conceptions de lentille intraoculaire modulaire, outils et procédés associés |
| JP6655610B2 (ja) | 2014-05-29 | 2020-02-26 | グローコス コーポレーション | 制御された薬物送達機能を備えるインプラント及びそれを使用する方法 |
| US9580896B2 (en) | 2014-07-05 | 2017-02-28 | John David Hopkins | Apparatus and method for prolonged active agent in aqueous systems |
| RU2695563C2 (ru) | 2014-07-15 | 2019-07-24 | Форсайт Вижн4, Инк. | Способ и устройство для доставки глазного имплантата |
| US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| CN114587774A (zh) | 2014-11-10 | 2022-06-07 | 弗赛特影像4股份有限公司 | 治疗眼睛的系统 |
| AU2015380300B2 (en) | 2015-01-30 | 2020-01-02 | Alcon Inc. | Modular intraocular lens designs |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| WO2017040853A1 (fr) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Implants d'administration de médicament présentant capacité d'administration bidirectionnelle |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| WO2017062770A1 (fr) | 2015-10-08 | 2017-04-13 | Silverberg Noah | Bouchon méatique et bioadhésifs |
| AU2016349363B2 (en) | 2015-11-04 | 2022-01-27 | Alcon Inc. | Modular intraocular lens designs, tools and methods |
| KR20180084104A (ko) | 2015-11-20 | 2018-07-24 | 포사이트 비젼4, 인크. | 연장 방출 약물 전달 장치를 위한 다공성 구조물 |
| AR108177A1 (es) | 2016-04-05 | 2018-07-25 | Forsight Vision4 Inc | Dispositivos de suministro de fármacos oculares implantables |
| JP7003110B2 (ja) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | 生体吸収性眼球薬物送達デバイス |
| US11045309B2 (en) | 2016-05-05 | 2021-06-29 | The Regents Of The University Of Colorado | Intraocular lens designs for improved stability |
| BR112019000059A2 (pt) | 2016-07-05 | 2019-10-01 | Janssen Biotech Inc | tratamento de doença vascular da retina com o uso de células progenitoras |
| US11382736B2 (en) | 2017-06-27 | 2022-07-12 | Alcon Inc. | Injector, intraocular lens system, and related methods |
| US11103460B2 (en) | 2017-08-07 | 2021-08-31 | Board Of Regents, The University Of Texas System | Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients |
| BR112020010053A2 (pt) | 2017-11-21 | 2020-11-03 | Forsight Vision4, Inc. | aparelho para troca de fluido para sistema de liberação de porta expansível e métodos de uso do mesmo |
| CN111971026A (zh) | 2018-05-24 | 2020-11-20 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| EP3801378A4 (fr) | 2018-05-24 | 2022-02-23 | Celanese EVA Performance Polymers LLC | Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire |
| US11779739B2 (en) * | 2018-12-21 | 2023-10-10 | Perfect Ip, Llc | Drug delivery system and method |
| JP7451732B2 (ja) | 2020-02-06 | 2024-03-18 | オキュラ セラピューティクス，インコーポレイテッド | 眼疾患を治療するための組成物及び方法 |
| WO2021195163A1 (fr) | 2020-03-25 | 2021-09-30 | Ocular Therapeutix, Inc. | Implant oculaire contenant un inhibiteur de tyrosine kinase |
| AU2021347318A1 (en) | 2020-09-24 | 2023-03-23 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine |
| US11357620B1 (en) | 2021-09-10 | 2022-06-14 | California LASIK & Eye, Inc. | Exchangeable optics and therapeutics |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2961629A (en) * | 1957-02-12 | 1960-11-22 | Lawrence J Kamm | Electrical connector for flexible cable |
| US3416530A (en) * | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
| US3896819A (en) * | 1969-04-01 | 1975-07-29 | Alejandro Zaffaroni | IUD having a replenishing drug reservoir |
| US3618604A (en) * | 1969-06-09 | 1971-11-09 | Alza Corp | Ocular insert |
| US3630200A (en) * | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3632739A (en) * | 1969-12-29 | 1972-01-04 | Sandoz Ag | Solid sustained release pharmaceutical preparation |
| US3980463A (en) * | 1970-11-16 | 1976-09-14 | Sumitomo Chemical Company, Limited | Process for producing granular composition for use in agriculture and horticulture |
| US3993071A (en) * | 1971-09-09 | 1976-11-23 | Alza Corporation | Bioerodible ocular device |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4036227A (en) * | 1973-04-25 | 1977-07-19 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
| US3961628A (en) * | 1974-04-10 | 1976-06-08 | Alza Corporation | Ocular drug dispensing system |
| US4096238A (en) * | 1974-12-23 | 1978-06-20 | Alza Corporation | Method for administering drug to the gastrointestinal tract |
| US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4034758A (en) * | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
| US3977404A (en) * | 1975-09-08 | 1976-08-31 | Alza Corporation | Osmotic device having microporous reservoir |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
| US4247498A (en) * | 1976-08-30 | 1981-01-27 | Akzona Incorporated | Methods for making microporous products |
| US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
| US4111201A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4519909A (en) * | 1977-07-11 | 1985-05-28 | Akzona Incorporated | Microporous products |
| US4186184A (en) * | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| JPS54119021A (en) * | 1978-03-06 | 1979-09-14 | Nippon Kayaku Co Ltd | Carcinostatic agent |
| US4290426A (en) * | 1978-05-04 | 1981-09-22 | Alza Corporation | Dispenser for dispensing beneficial agent |
| US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4730013A (en) * | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
| US4439196A (en) * | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| DK90883A (da) * | 1982-03-18 | 1983-09-19 | Merck & Co Inc | Beholder til osmotisk afgivelse af et stof eller en stofblanding |
| US4475916A (en) * | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4432965A (en) * | 1982-07-09 | 1984-02-21 | Key Pharmaceuticals, Inc. | Quinidine sustained release dosage formulation |
| US4519801A (en) * | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
| US4522625A (en) * | 1982-09-29 | 1985-06-11 | Alza Corporation | Drug dispenser comprising wall formed of semipermeable member and enteric member |
| US4673405A (en) * | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
| US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4777049A (en) * | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
| EP0147780A3 (fr) * | 1984-01-03 | 1987-03-11 | Merck & Co. Inc. | Dispositif pour la libération d'un médicament |
| IT1206166B (it) * | 1984-07-26 | 1989-04-14 | Sigma Tau Ind Farmaceuti | Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione |
| US4692336A (en) * | 1984-03-19 | 1987-09-08 | Alza Corporation | Self controlled release device for administering beneficial agent to recipient |
| US4716031A (en) * | 1984-03-21 | 1987-12-29 | Alza Corporation | Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug |
| US4615698A (en) * | 1984-03-23 | 1986-10-07 | Alza Corporation | Total agent osmotic delivery system |
| US4657543A (en) * | 1984-07-23 | 1987-04-14 | Massachusetts Institute Of Technology | Ultrasonically modulated polymeric devices for delivering compositions |
| US4927687A (en) * | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4913906B1 (en) * | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| US4609374A (en) * | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
| US4624847A (en) * | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
| US4693886A (en) * | 1985-04-22 | 1987-09-15 | Alza Corporation | Osmotic device with inert core |
| US4720384A (en) * | 1985-05-03 | 1988-01-19 | E. I. Du Pont De Nemours And Company | Manufacture of hollow fine tubular drug delivery systems |
| US4898733A (en) * | 1985-11-04 | 1990-02-06 | International Minerals & Chemical Corp. | Layered, compression molded device for the sustained release of a beneficial agent |
| US4717567A (en) * | 1985-11-25 | 1988-01-05 | Eastman Kodak Company | Rumen-stable pellets |
| IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| US5141752A (en) * | 1986-05-09 | 1992-08-25 | Alza Corporation | Delayed drug delivery device |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4786500A (en) * | 1986-06-26 | 1988-11-22 | Alza Corporation | Programmable agent delivery system |
| JPH0794384B2 (ja) * | 1986-09-01 | 1995-10-11 | 帝国製薬株式会社 | 徐放性口腔内用製剤 |
| US4806382A (en) * | 1987-04-10 | 1989-02-21 | University Of Florida | Ocular implants and methods for their manufacture |
| US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
| US4891223A (en) * | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
| US4994273A (en) * | 1987-11-02 | 1991-02-19 | Merck & Co., Inc. | Solubility modulated drug delivery device |
| IT1223150B (it) * | 1987-11-18 | 1990-09-12 | Ubaldo Conte | Compressa per uso oftalmico e rilascio controllato della sostanza attiva |
| US4877618A (en) * | 1988-03-18 | 1989-10-31 | Reed Jr Fred D | Transdermal drug delivery device |
| US4882150A (en) * | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US4865846A (en) * | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
| US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| US5098443A (en) * | 1989-03-23 | 1992-03-24 | University Of Miami | Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents |
| US5028435A (en) * | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
| DE69101313T2 (de) * | 1990-01-30 | 1994-06-30 | Akzo Nv | Gegenstand zur gesteuerten wirkstoffabgabe mit einem von einer wand völlig umschlossenen hohlraum und völlig oder teilweise mit einem oder mehreren wirkstoffen gefüllt. |
| US5091185A (en) * | 1990-06-20 | 1992-02-25 | Monsanto Company | Coated veterinary implants |
| US5525601A (en) * | 1990-09-07 | 1996-06-11 | Universidad De Alicante | Composition for treating ocular pain |
| IS3778A7 (is) * | 1990-10-31 | 1992-05-02 | Amgen Inc. | Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5435998A (en) * | 1994-08-03 | 1995-07-25 | Abelson; Mark B. | Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents |
-
1997
- 1997-08-28 US US08/919,221 patent/US5902598A/en not_active Expired - Lifetime
-
1998
- 1998-08-27 TW TW087114137A patent/TWI222884B/zh not_active IP Right Cessation
- 1998-08-28 CA CA002301685A patent/CA2301685C/fr not_active Expired - Fee Related
- 1998-08-28 ME MEP-200/08A patent/MEP20008A/xx unknown
- 1998-08-28 EP EP98942180A patent/EP1009388B1/fr not_active Expired - Lifetime
- 1998-08-28 WO PCT/US1998/017342 patent/WO1999011244A1/fr active Application Filing
- 1998-08-28 SG SG200203462A patent/SG121718A1/en unknown
- 1998-08-28 PL PL98344039A patent/PL344039A1/xx unknown
- 1998-08-28 AR ARP980104323A patent/AR017026A1/es not_active Application Discontinuation
- 1998-08-28 JP JP2000508347A patent/JP4530531B2/ja not_active Expired - Fee Related
- 1998-08-28 ME MEP-2008-200A patent/ME00122B/me unknown
- 1998-08-28 IL IL13456898A patent/IL134568A/xx not_active IP Right Cessation
- 1998-08-28 CN CNA2007101933400A patent/CN101327197A/zh active Pending
- 1998-08-28 HU HU0002797A patent/HUP0002797A3/hu unknown
- 1998-08-28 TR TR2000/01029T patent/TR200001029T2/xx unknown
- 1998-08-28 AT AT98942180T patent/ATE548029T1/de active
- 1998-08-28 KR KR1020007001996A patent/KR20010023358A/ko not_active Application Discontinuation
- 1998-08-28 NZ NZ502836A patent/NZ502836A/xx unknown
- 1998-08-28 RS YU11100A patent/RS52096B/sr unknown
- 1998-08-28 UA UA2000031729A patent/UA71898C2/uk unknown
- 1998-08-28 AU AU90291/98A patent/AU741846B2/en not_active Ceased
- 1998-08-28 BR BR9811381-0A patent/BR9811381A/pt not_active Application Discontinuation
- 1998-08-28 CZ CZ20000604A patent/CZ302339B6/cs not_active IP Right Cessation
- 1998-08-28 CN CNB988103753A patent/CN100453074C/zh not_active Expired - Fee Related
- 1998-08-28 EA EA200000267A patent/EA002162B1/ru not_active IP Right Cessation
-
2000
- 2000-02-14 NO NO20000735A patent/NO327752B1/no not_active IP Right Cessation
-
2001
- 2001-08-13 HK HK01105631.3A patent/HK1035135A1/xx not_active IP Right Cessation
-
2002
- 2002-03-11 NZ NZ517736A patent/NZ517736A/en not_active IP Right Cessation
-
2010
- 2010-03-01 JP JP2010044187A patent/JP2010168388A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA71898C2 (en) | Sustained release drug delivery system | |
| US9849085B2 (en) | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | |
| EP1347741B1 (fr) | Dispositifs d'administration de medicament a liberation prolongee pour la diffusion d'agents multiples | |
| EP1404295B1 (fr) | Dispositifs de liberation prolongee de medicaments comprenant des noyaux de medicaments enrobes | |
| US20020110591A1 (en) | Sustained release drug delivery devices | |
| US20040062787A1 (en) | Therapeutic combination of amlodipineand benazepril/benazeprilat | |
| EP1847255A2 (fr) | Dispositifs de livraison de médicaments à libération prolongée avec noyaux de médicaments recouverts | |
| MXPA00001941A (en) | Sustained release drug delivery devices |